Drug Trial Radar · NCT05895786
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
318
Planned (sponsor's estimate)
Start
May 20, 2023
Primary completion
Jul 29, 2030
Study completion Jul 29, 2030
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM. This study is seeking participants who: * Are 18 years of age or older or minimum legal adult age as defined per local regulation, whichever is greater * Have active DM or active PM. * Are receiving a stable dose of 1 corticosteroid taken by mouth and/or 1 traditional immunosuppressant. * Note: Corticosteroids and immunosuppressants are medicines that help reduce inflammation and may signal to the immune system not to attack the body. Dermatomyositis (DM) is a rare disease that causes muscle inflammation that results in muscle weakness and low muscle stamina. Patients with DM have a characteristic skin rash. Polymyositis (PM) is a rare disease that involves mainly muscle inflammation resulting in muscle weakness, that can sometimes be painful. Patients with DM and PM may have trouble going up the steps, walking or getting to a standing position. Some of the participants will receive the study medicine (dazukibart) and some will receive placebo (which is similar to study medicine but contains no medicine in it). The study medicine or placebo will be given as an intravenous (IV) infusion (directly into the veins), which takes about 1 hour; every 4 weeks from Day 1 to Week 48 of the study. Both dazukibart and placebo and will be given at the study site. The study will compare the experiences of people receiving study medication to those of the people who do not. This will help to see if dazukibart is safe and effective. Participants will take part in this study for about 13 months. During this time, participants will have 15 study visits. These visits will be performed at the study site.
Conditions
- Myositis
Interventions
PF-06823859Drug
anti-interferon beta therapy
PlaceboDrug
Placebo for PF-06823859
Primary outcomes
What the sponsor says the trial is designed to measure.
- Moderate change in Total Improvement Score (TIS)Time frame: 24 weeks outside of the United States (US) and 52 weeks in the US
Locations
138 sites in 20 countries. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Research, PLLC
Glendale, Arizona · Recruiting
Neuromuscular Research Center
Phoenix, Arizona · Recruiting
Mayo Clinic Hospital
Phoenix, Arizona · Recruiting
Mayo Clinic in Arizona - Scottsdale
Scottsdale, Arizona · Recruiting
200 UCLA Medical Plaza
Los Angeles, California · Recruiting
UCLA Clinical & Translational Research Center (CTRC)
Los Angeles, California · Recruiting
UCLA
Los Angeles, California · Recruiting
Center for Clinical Research - Chapman Pavilion
Orange, California · Active not recruiting
UCI Douglas Hospital
Orange, California · Active not recruiting
UCI Health Center for Innovative Health Therapies
Orange, California · Active not recruiting
University of California - Irvine
Orange, California · Active not recruiting
Samir Macwan, M.D., Inc.
Rancho Mirage, California · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Lal Bhagchandani, M.D
Margate, Florida · Active not recruiting
University of Miami
Miami, Florida · Recruiting
University of Miami Dermatology Clinical Trials Unit
Miami, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
Unviversity of Miami
Miami, Florida · Recruiting
Omega Research Orlando
Orlando, Florida · Active not recruiting
IRIS Research and Development, LLC
Plantation, Florida · Recruiting
West Broward Pulmonary Consultants
Plantation, Florida · Recruiting
West Broward Rheumatology Associates
Tamarac, Florida · Active not recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
CTC - Brigham & Women's Hospital
Boston, Massachusetts · Recruiting
CTH - Brigham & Women's Hospital
Boston, Massachusetts · Recruiting
Washington University Pulmonary Function Laboratory
St Louis, Missouri · Active not recruiting
Washington University School of Medicine
St Louis, Missouri · Active not recruiting
NYU Langone Health - Clinical and Translational Science Institute Research Pharmacy
New York, New York · Recruiting
NYU Langone Health Clinical Research Center
New York, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
NYU Langone Radiology
New York, New York · Recruiting
Hospital for Special Surgery - Belaire
New York, New York · Not yet recruiting
Hospital for Special Surgery
New York, New York · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
RAO Research LLC
Oklahoma City, Oklahoma · Recruiting
UPMC Arthritis and Autoimmunity Center, Falk Clinic
Pittsburgh, Pennsylvania · Recruiting
UPMC Montefiore Clinical and Translational Research Center (CTRC)
Pittsburgh, Pennsylvania · Recruiting
UPMC Presbyterian Shadyside Hospital
Pittsburgh, Pennsylvania · Recruiting
Integrative Rheumatology of South Texas
Edinburg, Texas · Recruiting
Arthritis & Rheumatology Research Institute, PLLC
Frisco, Texas · Recruiting
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.